Journal · Updated 2026-08-11

The 2026 GLP-1 Market Ledger: Every Entry, Exit, and Pivot Our Database Has Recorded

By the GLP1ProviderFinder Research Desk · Medically reviewed by Dr. A. Goher, MD · Last reviewed 2026-08-11 · How we verify

The exits and the enforcement gravity

The pattern in the departures is legal gravity doing its work. Hims' arc compresses the whole era: a forty-nine-dollar compounded semaglutide offer in February 2026, Novo's response, a March 9 settlement, and a brand-only storefront by spring — the fastest public demonstration that the post-shortage copies lane had closed for the biggest players first, because the biggest players make the clearest targets. Ro's quieter pivot to the same shape, the standing exclusion of the sub-$100 figures that no live page would confirm, and the earlier wind-downs our corrections log inherited all rhyme: what exited was scale-without-documentation, and what remained had to pick a lane — brand channel with a service layer, or documented-need 503A with the compliance costs priced in. That second lane's costs are exactly why our flagship guide treats the two-forty-nine-to-five-forty-nine band as the compliant market's center of gravity, and why figures far below it carry watch-flags rather than crowns.

The entries, the squeeze, and what the pattern predicts

The August intake of thirteen tracked programs looks like expansion and functions as revelation — most existed before we could verify them, and their entry moved the honest floors (bmiMD's ninety-nine-committed semaglutide displacing prior leaders; Trimi and LumiMeds' one twenty-five annual tirzepatide, upfront-billed) while adding the funnel-gated cohort whose real prices our capture pipeline is built to land. Above them, the manufacturers spent 2025–26 doing what compounders can't: cutting list. The brand floor's fall — four forty-nine vials, one forty-nine tablets, a one ninety-nine pen introduction — compressed the compounded value proposition from "one-third the price" toward "half the price with more homework," which is a different pitch. The prediction the pattern supports, stated for the record and revisitable in this ledger's next edition: continued thinning of the unverifiable low end, at least one more marquee pivot or settlement, further brand-price pressure timed to enforcement wins, and a compounded market whose survivors look increasingly like the disclosed-network, labeled-promo, flat-price shape — because in a consolidating market under legal scrutiny, verifiability itself becomes the moat. Which is, not coincidentally, the thesis this entire site is built on.

This article is pricing research, not medical advice. Verify figures at the provider's checkout. Nothing here is medical advice.